Literature DB >> 17872501

Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology.

Alwin Scharstuhl1, Bernhard Schewe, Karin Benz, Christoph Gaissmaier, Hans-Jörg Bühring, Reinout Stoop.   

Abstract

Osteoarthritis (OA) is a multifactorial disease strongly correlated with history of joint trauma, joint dysplasia, and advanced age. Mesenchymal stem cells (MSCs) are promising cells for biological cartilage regeneration. Conflicting data have been published concerning the availability of MSCs from the iliac crest, depending on age and overall physical fitness. Here, we analyzed whether the availability and chondrogenic differentiation capacity of MSCs isolated from the femoral shaft as an alternative source is age- or OA etiology-dependent. MSCs were isolated from the bone marrow (BM) of 98 patients, categorized into three OA-etiology groups (age-related, joint trauma, joint dysplasia) at the time of total hip replacement. All BM samples were characterized for cell yield, proliferation capacity, and phenotype. Chondrogenic differentiation was studied using micromass culture and analyzed by histology, immunohistochemistry, and quantitative reverse transcriptase-polymerase chain reaction. Significant volumes of viable BM (up to 25 ml) could be harvested from the femoral shaft without observing donor-site morbidity, typically containing >10(7) mononuclear cells per milliliter. No correlation of age or OA etiology with the number of mononuclear cells in BM, MSC yield, or cell size was found. Proliferative capacity and cellular spectrum of the harvested cells were independent of age and cause of OA. From all tested donors, MSCs could be differentiated into the chondrogenic lineage. We conclude that, irrespective of age and OA etiology, sufficient numbers of MSCs can be isolated and that these cells possess an adequate chondrogenic differentiation potential. Therefore, a therapeutic application of MSCs for cartilage regeneration of OA lesions seems feasible. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Year:  2007        PMID: 17872501     DOI: 10.1634/stemcells.2007-0300

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  67 in total

1.  Changes of the Functional Capacity of Mesenchymal Stem Cells due to Aging or Age-Associated Disease - Implications for Clinical Applications and Donor Recruitment.

Authors:  Günter Lepperdinger; Regina Brunauer; Robert Gassner; Angelika Jamnig; Frank Kloss; Gerhard Thomas Laschober
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

2.  Cartilage matrix formation by bovine mesenchymal stem cells in three-dimensional culture is age-dependent.

Authors:  Isaac E Erickson; Steven C van Veen; Swarnali Sengupta; Sydney R Kestle; Robert L Mauck
Journal:  Clin Orthop Relat Res       Date:  2011-10       Impact factor: 4.176

3.  Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1.

Authors:  Venkata Lokesh Battula; Sabrina Treml; Petra M Bareiss; Friederike Gieseke; Helene Roelofs; Peter de Zwart; Ingo Müller; Bernhard Schewe; Thomas Skutella; Willem E Fibbe; Lothar Kanz; Hans-Jörg Bühring
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

Review 4.  Mesenchymal stem cells in joint disease and repair.

Authors:  Frank Barry; Mary Murphy
Journal:  Nat Rev Rheumatol       Date:  2013-07-23       Impact factor: 20.543

5.  Donor Variation and Optimization of Human Mesenchymal Stem Cell Chondrogenesis in Hyaluronic Acid.

Authors:  Minwook Kim; Isaac E Erickson; Alice H Huang; Sean T Garrity; Robert L Mauck; David R Steinberg
Journal:  Tissue Eng Part A       Date:  2018-09-21       Impact factor: 3.845

6.  Umbilical cord as a mesenchymal stem cell source for treating joint pathologies.

Authors:  Maria Carmen Arufe; Alexandre De la Fuente; Isaac Fuentes; Francisco Javier De Toro; Francisco Javier Blanco
Journal:  World J Orthop       Date:  2011-06-18

7.  Dual non-viral gene delivery from microparticles within 3D high-density stem cell constructs for enhanced bone tissue engineering.

Authors:  Alexandra McMillan; Minh Khanh Nguyen; Tomas Gonzalez-Fernandez; Peilin Ge; Xiaohua Yu; William L Murphy; Daniel J Kelly; Eben Alsberg
Journal:  Biomaterials       Date:  2018-01-03       Impact factor: 12.479

8.  A cis-regulatory site downregulates PTHLH in translocation t(8;12)(q13;p11.2) and leads to Brachydactyly Type E.

Authors:  Philipp G Maass; Jutta Wirth; Atakan Aydin; Andreas Rump; Sigmar Stricker; Sigrid Tinschert; Miguel Otero; Kaneyuki Tsuchimochi; Mary B Goldring; Friedrich C Luft; Sylvia Bähring
Journal:  Hum Mol Genet       Date:  2009-12-16       Impact factor: 6.150

9.  Changes in Chondrogenic Progenitor Populations Associated with Aging and Osteoarthritis.

Authors:  Kyla Brady; Sally C Dickinson; Anthony P Hollander
Journal:  Cartilage       Date:  2015-03-24       Impact factor: 4.634

Review 10.  Tissue engineering in the rheumatic diseases.

Authors:  Jochen Ringe; Michael Sittinger
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.